Biology Reference
In-Depth Information
drome lymphoma cell lines: Ig binding speci®city and VH-gene putative somatic mutation
analysis [published erratum appears in Blood 1994; 84: 995]. Blood 83: 1067±1078.
Ng VL, Hurt MH, Herndier BG, Fry KE, McGrath MS. 1997. VH gene use by HIV type 1-
associated lymphoproliferations. AIDS Res Hum Retroviruses 13: 135±149.
Ngo VN, Tang HL, Cyster JG. 1998. Epstein-Barr virus-induced molecule 1 ligand chemokine is
expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated
B cells. J Exp Med 188: 181±191.
Ngo VN, Korner H, Gunn MD, Schmidt KN, Riminton DS, Cooper MD, Browning JL, Sedgwick
JD, Cyster JG. 1999. Lymphotoxin alpha/beta and tumor necrosis factor are required for
stromal cell expression of homing chemokines in B and T cell areas of the spleen. J Exp Med
189: 403±412.
Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF, Monte®ori D, Oren-
stein JM, Fox C, Schrager LK, et al. 1995. Studies in subjects with long-term nonprogressive
human immunode®ciency virus infection [see comments]. N Engl J Med 332: 209±216.
Pinchuk LM, Polacino PS, Agy MB, Klaus SJ, Clark EA. 1994. The role of CD40 and CD80
accessory cell molecules in dendritic cell-dependent HIV-1 infection. Immunity 1: 317±325.
Polacino P, Stallard V, Monte®ori DC, Brown CR, Richardson BA, Morton WR, Benveniste RE,
Hu SL. 1999. Protection of macaques against intrarectal infection by a combination immuniza-
tion regimen with recombinant simian immunode®ciency virus SIVmne gp160 vaccines. J Virol
73: 3134±3346.
Pope M, Gezelter S, Gallo N, Ho¨man L, Steinman RM. 1995. Low levels of HIV-1 infection in
cutaneous dendritic cells promote extensive viral replication upon binding to memory CD4
T
cells. J Exp Med 182: 2045±2056.
Poulin L, Paquette N, Moir S, Lapointe R, Darveau A. 1994. Productive infection of normal
CD40-activated human B lymphocytes by HIV-1. AIDS 8: 1539±1544.
PrÂvot S, Raphael M, Fournier JG, Diebold J. 1993. Detection by in situ hybridization of HIV and
c-myc RNA in tumour cells of AIDS-related B-cell lymphomas. Histopathology 22: 151±156.
Przybylski GK, Goldman J, Ng VL, McGrath MS, Herndier BG, Schenkein DP, Monroe JG,
Silberstein LE. 1996. Evidence for early B-cell activation preceding the development of Epstein-
Barr virus-negative acquired immunode®ciency syndrome-related lymphoma. Blood 88: 4620±
4629.
Puri RK, Aggarwal BB. 1992. Human immunode®ciency virus type 1 tat gene up-regulates inter-
leukin 4 receptors on a human B-lymphoblastoid cell line. Cancer Res 52: 3787±3790.
Puthier D, Derenne S, Barille S, Moreau P, Harousseau JL, Bataille R, Amiot M. 1999. Mcl-1 and
Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br J Haematol 107: 392±395.
Racz P, Tenner-Racz K, Kahl C, Feller AC, Kern P, Dietrich M. 1986. Spectrum of morphologic
changes of lymph nodes from patients with AIDS or AIDS-related complexes. Prog Allergy 37:
81±181.
Re MC, Furlini G, Vignoli M, Ramazzotti E, Roderigo G, De Rosa V, Zauli G, Lolli S, Capitani
S, La Placa M. 1995. E¨ect of antibody to HIV-1 Tat protein on viral replication in vitro and
progression of HIV-1 disease in vivo. J Acquir Immune De®c Syndr Hum Retrovirol 10: 408±416.
Reiser H, Stadecker MJ. 1996. Costimulatory B7 molecules in the pathogenesis of infectious and
autoimmune diseases. N Engl J Med 335: 1369±1377.
Reiss P, Lange JM, de Ronde A, de Wolf F, Dekker J, Debouck C, Goudsmit J. 1990. Speed of
progression to AIDS and degree of antibody response to accessory gene products of HIV-1. J
Med Virol 30: 163±168.
Robinson Jr WE, Monte®ori DC, Mitchell WM. 1988. Antibody-dependent enhancement of
human immunode®ciency virus type-1 infection. Lancet i: 790.
Rodriguez-Alfageme C, Chen Z, Sonoda G, Testa JR, Damiani RD, Astrin SM. 1998. B cells
malignantly transformed by human immunode®ciency virus are polyclonal. Virology 252: 34±38.
